Policy overhaul could see waiting times reduced for underserved member states, pharma group says
Pharmaceutical companies in Europe have pledged to implement fairer pricing and delivery policies in response to concerns that patients in some EU countries are waiting almost two and a half years for new medicines.
Publishing a strategy paper on 11 April, the European Federal of Pharmaceutical Industries and Associations (Efpia) said new proposals including a commitment to transparent drug pricing across the EU would “reduce inequalities in patient access to medicines across Europe”.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.